Nervgen Pharma reported total assets of $65.20M and total liabilities of $65.20M for the quarter ended Jun 2026. This balance sheet covers 4 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Dec2024 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & EquivalentsCash & Equiv. | 12.36M | 15.83M | 12.07M | 62.74M |
| Receivables - NetNet Receivables | 0.30M | 0.06M | 0.07M | 0.14M |
| Receivables | 0.30M | 0.06M | 0.07M | 0.14M |
| Prepaid Assets | 0.59M | 0.46M | 2.71M | 1.95M |
| Current Assets | 13.61M | 16.35M | 14.85M | 64.93M |
| Non-Current Assets | ||||
| Property, Plant & Equipment (Net) | 0.34M | 0.29M | 0.29M | 0.28M |
| Intangibles | 0.33M | 0.29M | 0.29M | 0.28M |
| Goodwill & Intangibles | 0.33M | 0.29M | 0.29M | 0.28M |
| Other Non-Current Assets | 0.29M | 0.09M | ||
| Non-Current Assets | 0.34M | 0.29M | 0.29M | 0.28M |
| Assets | 13.95M | 16.64M | 15.14M | 65.20M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payables | 3.54M | 3.34M | 4.29M | 3.10M |
| Payables | 3.54M | 3.34M | 4.29M | 3.10M |
| Short term Debt | 0.07M | 0.01M | ||
| Current Leases | 0.07M | 0.01M | ||
| Total Current Liabilities | 12.10M | 14.15M | 11.10M | 52.71M |
| Non-Current Liabilities | ||||
| Operating Leases | 0.01M | 0.01M | ||
| Other Non-Current Liabilities | 8.49M | 10.80M | 6.81M | 49.61M |
| Total Non-Current Liabilities | 0.01M | 5.84M | 8.33M | 15.59M |
| Total Liabilities | 12.10M | 16.64M | 15.14M | 65.20M |
| Shareholder's Equity | ||||
| Total Debt | 0.07M | 0.01M | ||
| Common Equity | 1.84M | 2.49M | 4.04M | 12.49M |
| Liabilities and Shareholders Equity | 13.95M | 16.64M | 15.14M | 65.20M |
| Retained Earnings | -73.48M | -105.24M | -108.24M | -128.43M |